The vice president of AstraZeneca ’s Cardiovascular and Metabolic Diseases Portfolio detailed the results from the phase 3 THALES trial, and where ticagrelor stands among other FDA approved stroke treatments.
Naeem Khan, MD
Advertisement
Articles by Naeem Khan, MD
Advertisement
Latest Updated Articles
Naeem Khan, MD: Ticagrelor Shines in Phase 3 THALES TrialPublished: July 25th 2020 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Fast Tracks Etalanetug, Encouraging Interim TEMPO-4 Data, Initial Data on Cell Therapy UX-DA001
2
Benzodiazepines and Antipsychotics Tied to Higher Mortality in Hospice Patients With Dementia
3
Incidence and Prevalence of Frontotemporal Dementia Similar to Dementia with Lewy Bodies, Meta-Analysis Shows
4
NeurologyLive® Friday 5 — October 24, 2025
5
